AvroBio Inc
Research AvroBio Inc (TECX) on Bullrun: market cap USD 725.36M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTECX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 725.36M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 22.29M
- Free cash flow-USD 21.53M
Valuation Snapshot
latest market cap is USD 725.36M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 74.15B | -USD 60.29M | n/a | -4.05 | USD 253.80M | USD 1.28M | USD 251.33M |
| FY2024 | USD 0 | -USD 57.98B | -USD 59.24M | n/a | -6.83 | USD 141.24M | USD 3.30M | USD 140.78M |
| FY2023 | n/a | -USD 42.82B | -USD 40.96M | n/a | -33.76 | USD 28.77M | USD 4.34M | -USD 84.64M |
| FY2022 | n/a | -USD 105.89M | -USD 97.48M | n/a | -2.42 | USD 92.56M | USD 15.00M | -USD 45.65M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 725.36M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 390.88M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 685.92M | n/a | n/a | n/a |
About AvroBio Inc
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AvroBio Inc's market cap?
AvroBio Inc's market capitalization is USD 725.36M.
What does AvroBio Inc do?
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.